ChemicalBook >> CAS DataBase List >>CC-223

CC-223

CC-223 structure

CAS No.: 1228013-30-6

Chemical Name:: CC-223

Synonyms: CC-223;CS-2039;CS-2163;ATG-008;Onatasertib;CC223;CC 223;Onatasertib (CC-223);Onatasertib(CC 223,ATG-008);mTOR,ATG008,Mammalian target of Rapamycin,inhibit,ATG-008,Onatasertib,Inhibitor,ATG 008,Apoptosis;7-[6-(2-Hydroxypropan-2-yl)pyridin-3-yl]-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one

CBNumber:: CB33041393

Molecular Formula:: C21H27N5O3

Molecular Weight:: 397.47

MDL Number:: MFCD28976054

MOL File:: 1228013-30-6.mol

Last updated:2023-06-08 09:02:45

Request For Quotation

CC-223 Properties

Boiling point	562.9±60.0 °C(Predicted)
Density	1.37±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	insoluble in H2O; ≥108 mg/mL in DMSO; ≥20.28 mg/mL in EtOH
form	crystalline solid
pka	13?+-.0.29(Predicted)
FDA UNII	I8RA3543SY

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS07

Signal word

Warning

Hazard statements

H302-H315-H319-H335

Precautionary statements

P261-P305+P351+P338

NFPA 704

	0
2		0

CC-223 price More Price(17)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Cayman Chemical	19917	CC-223 ≥98%	1228013-30-6	1mg	$49	2024-03-01	Buy
Cayman Chemical	19917	CC-223 ≥98%	1228013-30-6	5mg	$179	2024-03-01	Buy
Cayman Chemical	19917	CC-223 ≥98%	1228013-30-6	10mg	$310	2024-03-01	Buy
Cayman Chemical	19917	CC-223 ≥98%	1228013-30-6	25mg	$534	2024-03-01	Buy
ChemScene	CS-4560	CC-223 99.43%	1228013-30-6	50mg	$900	2021-12-16	Buy

Product number	Packaging	Price	Buy
19917	1mg	$49	Buy
19917	5mg	$179	Buy
19917	10mg	$310	Buy
19917	25mg	$534	Buy
CS-4560	50mg	$900	Buy

CC-223 Chemical Properties,Uses,Production

Description

CC-223 is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, demonstrating inhibition of mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems. After tumor-bearing mice was treated with CC-223 for a single oral dose. It exhibited dose-dependent tumor growth inhibition in multiple solid tumor xenografts. The observed antitumor activity of CC-223 is likely to be mediated through inhibition of both mTORC1 and mTORC2. CC-223 is currently in phase I clinical trials for its treatment of advanced solid and hematologic cancers.

References

Varga, Andrea, et al. "Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors." Journal of Clinical Oncology 31.15(2013):-.
Mortensen, D. S., et al. "CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization." Molecular Cancer Therapeutics 14.6(2015):1295.
Goy, A, et al. "Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM)." Neuroendocrinology 43.3(2013):276-276.
Shih, Kent C, et al. "Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers." Journal of Clinical Oncology (2012).

Description

CC-223 is a potent inhibitor of mTOR (IC₅₀ = 16 nM) that shows selectivity for mTOR over a panel of 246 other kinases. It blocks signaling through both mTORC1 and mTORC2, inhibiting the phosphorylation of S6RP, 4EBP1, and Akt(S473) in cellular systems. CC-223 inhibits growth and induces apoptosis in hematologic and solid tumor cell lines in vitro, and it exhibits dose-dependent tumor growth inhibition in multiple solid tumor xenografts in vivo.

in vitro

cc-223 was identified as an atp–competitive inhibitor of the mtor kinase targeting mtorc1 of both 4ebp1 and p70 s6 kinase 1 and mtorc2, which prevented the upregulation of akt phosphorylation. moreover, cc-223 was selectively potent to mtor kinase while showed more than 150-fold sensitivity against the related lipid kinase, pi3ka. in addition, cc-223 was active over many non-hodgkin lymphoma cell lines and solid tumor lines such as including glioma, breast, hepatocellular carcinoma, as well as non–small cell lung cancer [1].

in vivo

in animal study, cc-223 was selected for evaluation in pc-3 tumor bearing efficacy mouse models. mice were orally treated with vehicle or various doses of cc-223 once daily or twice daily at a dose of 5 ml/kg for 21 days, and the final reductions of tumor volume were measured following the final day of dosing. results showed that all cc-223 had dose- and schedule-dependent inhibition of tumor growth in the pc-3 model. moreover, the maximum observed efficacy for cc-223 was determined to be 87%, at its tolerated dose of 25 mg/kg q.d. [1].

IC 50

16 nm

References

[1] mortensen ds, et al. discovery of mammalian target of rapamycin (mtor) kinase inhibitor cc-223. j med chem. 2015 jul 9;58(13):5323-5333.
[2] bendell jc, et al. a phase i dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mtorc1/mtorc2 kinase inhibitor cc-223 in patients with advanced solid tumors or multiple myeloma. cancer. 2015 oct 1;121(19):3481-90.

CC-223 Preparation Products And Raw materials

Raw materials

Preparation Products

CC-223 Suppliers

Global( 80)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32686	60
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
career henan chemical co	+86-0371-86658258 15093356674;	factory@coreychem.com	China	29826	58
HANGZHOU CLAP TECHNOLOGY CO.,LTD	86-571-88216897,88216896 13588875226	sales@hzclap.com	CHINA	6313	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10523	58
InvivoChem	+1-708-310-1919 +1-13798911105	sales@invivochem.cn	United States	6393	58
TargetMol Chemicals Inc.	+1-781-999-5354	support@targetmol.com	United States	19973	58
ShenZhen Trendseen Biological Technology Co.,Ltd.	13417589054	trendseenbio@gmail.com	China	11681	58
Hebei Miaoyin Technology Co.,Ltd	+86-17367732028 +86-17367732028	kathy@hbyinsheng.com	China	3582	58
Aladdin Scientific	+1-833-552-7181	sales@aladdinsci.com	United States	57511	58

Supplier	Advantage
ATK CHEMICAL COMPANY LIMITED	60
BOC Sciences	58
career henan chemical co	58
HANGZHOU CLAP TECHNOLOGY CO.,LTD	58
Zhejiang J&C Biological Technology Co.,Limited	58
InvivoChem	58
TargetMol Chemicals Inc.	58
ShenZhen Trendseen Biological Technology Co.,Ltd.	58
Hebei Miaoyin Technology Co.,Ltd	58
Aladdin Scientific	58

View Lastest Price from CC-223 manufacturers

Image	Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
	2019-12-24	7-[6-(2-Hydroxy-2-propanyl)-3-pyridinyl]-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one 1228013-30-6	US $1.00 / KG	1KG	Min98% HPLC	g/kg/ton	Career Henan Chemical Co

7-[6-(2-Hydroxy-2-propanyl)-3-pyridinyl]-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
1228013-30-6
US $1.00 / KG
Min98% HPLC
Career Henan Chemical Co

CC-223 Spectrum

CC-223(1228013-30-6)¹HNMR

1228013-30-6(CC-223)Related Search:

ABT-639 5-(9-isopropyl-2-Morpholino-9H-purin-6-yl)pyriMidin-2-aMine URMC-099 N-[4-[(2-Methoxyethyl)methylamino]phenyl]-2-phenyl-5-(trifluoromethyl)-4-oxazolecarboxamide (S)-3-(aMinoMethyl)-7-(3-hydroxypropoxy)benzo[c][1,2]oxaborol-1(3H)-ol

CC-223 7-[6-(2-Hydroxypropan-2-yl)pyridin-3-yl]-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one Pyrazino[2,3-b]pyrazin-2(1H)-one, 3,4-dihydro-7-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-(trans-4-methoxycyclohexyl)- Onatasertib 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)-3,4-dihydropyrazino-[2,3-b]pyrazin-2(1H)-one CS-2163 CS-2039 CC223;CC 223 7-[6-(2-Hydroxy-2-propanyl)-3-pyridinyl]-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one Onatasertib(CC 223,ATG-008) Onatasertib (CC-223) mTOR,ATG008,Mammalian target of Rapamycin,inhibit,ATG-008,Onatasertib,Inhibitor,ATG 008,Apoptosis ATG-008 1228013-30-6 Anti-cancer Inhibitor